Large B-Cell Lymphoma (LBCL) can be difficult to treat, especially for patients who relapse after standard chemotherapy, stem cell transplantation, or targeted therapies. In recent years, CAR-T cell therapy has emerged as one of the most advanced treatments available worldwide, offering new hope for patients who previously had limited options.
China is now one of the global leaders in CAR-T therapy development and clinical application, with multiple approved products, state-of-the-art treatment centers, and extensive experience in treating international patients.
Why Choose CAR-T Therapy in China for LBCL?
- Proven Results: Chinese clinical trials in LBCL patients report high complete response (CR) rates and durable remission in relapsed/refractory cases.
- Multiple Approved Products: Several CAR-T therapies for LBCL are already approved and available in China, compared to limited availability in many other countries.
- Fast Access: Patients can often access CAR-T therapy in China more quickly than in the U.S. or Europe, where waiting lists and strict trial enrollment can delay treatment.
- Cost Advantage: The overall treatment package in China can be significantly lower compared to Western countries, while maintaining world-class medical standards.
- International Patient Services: Multilingual medical teams, patient coordinators, and customized support ensure smooth communication and comfort throughout the treatment journey.
What’s Included in Our CAR-T Therapy Package
Our CAR-T cell therapy package for LBCL in China is designed to provide end-to-end medical care, from pre-evaluation to post-treatment follow-up.
1. Pre-Treatment Evaluation
- Comprehensive review of your medical history and reports
- Online consultation with top Chinese hematology-oncology specialists
- Individualized treatment plan and risk assessment
2. Arrival & Initial Workup
- VIP airport pickup and hospital admission assistance
- Complete diagnostic tests (blood tests, PET-CT, bone marrow if required)
- Evaluation of eligibility for CAR-T therapy
3. Leukapheresis & CAR-T Manufacturing
- Collection of T cells through leukapheresis
- Genetic engineering and expansion of CAR-T cells in GMP-certified labs (usually 2–4 weeks)
4. Conditioning & CAR-T Infusion
- Lymphodepletion chemotherapy (to prepare the body for CAR-T cells)
- CAR-T cell infusion under strict hospital monitoring
- Management of side effects (CRS, neurotoxicity, infections) with experienced ICU support
5. Recovery & Monitoring
- Regular blood tests and imaging to assess response
- Supportive care and infection prevention
- Discharge planning with detailed recovery guidelines
6. Follow-Up Services
- 3–6 month post-therapy follow-up (in China or remotely)
- Coordination with your local oncologist for long-term care
- Optional health screening and wellness services
Duration of Treatment in China
- Average hospital stay: 6–8 weeks
- Total recommended time in China: 2–3 months (including monitoring after infusion)
Eligibility for CAR-T Therapy in LBCL
CAR-T therapy is generally recommended for:
- Patients with relapsed or refractory LBCL after at least 2 lines of prior treatment
- Patients with adequate heart, liver, and kidney function
- Patients without uncontrolled infections or serious comorbidities
Why Having CAR-T cell Therapy in China?
We partner with leading CAR-T medical centers in Beijing, Shanghai, Guangzhou, and other cities, ensuring access to the latest therapies, expert hematology teams, and international patient care.
Our role is to:
- Connect you with top Chinese CAR-T specialists
- Simplify the process of medical record review and acceptance
- Provide end-to-end logistical and language support
- Ensure transparency on costs and treatment schedules
Estimated Cost of CAR-T Therapy Package for LBCL in China
The total cost of CAR-T therapy in China is generally 50–70% lower compared to the United States or Europe, where treatment expenses can exceed USD 500,000.
Additional Costs to Consider
- Travel & accommodation for family members (outside hospital)
- Food
- Interpreter & concierge services (included in our packages, optional upgrades available)
- Post-discharge stay in China for monitoring (2–4 weeks recommended)
Why Costs Are Lower in China
- Domestic production of CAR-T therapies reduces manufacturing expenses
- More treatment centers and approved products create competitive pricing
- Government and hospital support for advanced therapies ensures accessibility
Note: The exact cost depends on the hospital, CAR-T product chosen, and the patient’s individual condition. A personalized quotation is provided after doctors review your medical records.
